Kristian Werling cited “a robust startup culture” of Chicago area life sciences companies for McDermott’s announced $1 million set-aside of fees to help such ventures. "This is something that regionally our lawyers were asking for and our potential clients were asking for,” Mr. Werling said of the move. Byron Kalogerou further explained that "often times we [McDermott] play sort of the capital connector role” in funding life science startups. “We’re able to essentially send their pitch papers” to the venture capital, private equity and strategic VC funds the Firm represents. “I think that we just recognized that … it’s critical to have all those constituents under one tent,” he added.